Ten years ago, it was hard for Chinese biopharmaceutical service companies to meet the requirements of a Western client. Today, there is a proliferation of companies such as WuXi Biologics, MabPlex, JHL Biotech and more.
Furthermore, recently in Asia:
- Eirgenix received approval from Japan's PMDA, opportuning it to sell to the Japanese market.
- Korea's Celltrion has budgeted $514 million over five years to build China's biggest biologics facility at a capacity of 120,000 litres, manufacturing Celltrion's own biologics and performing contract work for Chinese biotechs.
- New mammalian production lines established by AGC biologics to produce monoclonal antibodies (MAbs) and fusion proteins
Contract biomanufacturing in Asia is poised for growth. If you're keen on understanding the Asian CMO landscape, check out IMAPAC's latest release - a 300 page directory, Asia-Pacific Biologic CMO Directory, gives you a comprehensive analysis of the CMOs in Asia. The report provides detailed research and analysis of the Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution, Financial Performance, Technologies Housed, and Facility Expansion Plans of 50+ CMOs in the Asian region from countries such as China, Taiwan, Korea, Japan, India, Singapore and more.
TABLE OF CONTENTS
SECTION 1
- PREFACE
- REPORT SCOPE & DATA COVERAGE
- IMAPAC'S RESEARCH METHODOLOGY
SECTION 2
- COMPANY-WISE DATA & ANALYSIS
- COMPANY OVERVIEW
- MANUFACTURING SITES
- FACILITY DESIGN
- PLANT CAPACITY
- BATCH SIZE
- GMP CERTIFICATION
- PRODUCTS MANUFACTURED
- MANUFACTURING SERVICES
- PROJECTS
- PARTNERSHIPS AND
- COLLABORATIONS
- CAPACITY PLANNING & FUTURE
- EXPANSION
- INTERVIEW
- INDUSTRY NEWS & UPDATES
- SWOT ANALYSIS
- REFERENCES
- Greater China
- 1. AMARAN BIOTECHNOLOGY
- 2. BOEHRINGER INGELHEIM
- 3. CMAB BIOPHARMA
- 4. CELLULAR BIOMEDICINE GROUP
- 5. CHIME BIOLOGICS
- 6. CP GOUJIAN PHARMA
- 7. EIRGENIX
- 8. INNOVENT BIOLOGICS
- 9. LONZA CHINA
- 10. MABPLEX
- 11. MYCENAX BIOTECH
- 12. OBIO TECHNOLOGY
- 13. ORIENT PHARMA
- 14. SINOBIOWAY
- 15. TARON SOLUTIONS
- 16. UNICOCELL
- 17. UNITED BIOPHARMA
- 18. WUXI APPTEC
- 19. 3S BIO
- Korea
- 20. ANTEROGEN
- 21. BINEX
- 22. EUBIOLOGICS
- 23. HANMI PHARMA
- 24. KOLON LIFE SCIENCES
- 25. MASTHERCELL
- 26. SAMSUNG BIOLOGICS
- Japan
- 27. AGC BIOLOGICS
- 28. AJINOMOTO BIO- PHARMA
- 29. BUSHU PHARMACEUTICALS
- 30. HITACHI CHEMICAL
- 31. ID PHARMA
- 32. MEDINET
- 33. PHARMABIO
- 34. TAKARA BIO
- 35. TOYOBO
- India
- 36. CLONZ BIOTECH
- 37. INTAS PHARMACEUTICALS
- 38. KEMWELL BIOPHARMA
- 39. STELIS BIOSOURCE
- 40. SYNGENE
- 41. ENZENE BIOLOGICS
- Australia
- 42. CELL THERAPIES
- 43. PFIZER CENTREONE
- 44. LUINA BIO SEA
- 45. BIOCON
- 46. ESCO ASTER
- 47. INNO BIOLOGICS
- 48. LONZA AG SINGAPORE
- 49. PT. KALBIO GLOBAL MEDIKA(KGM)
- 50. TCELS
SECTION 3: REGION-WISE DATA & ANALYSIS OF CMO'S {REGIONS COVERED: CHINA, TAIWAN, JAPAN& KOREA, INDIA, AUSTRALIA & SEA}
- PRODUCTS MANUFACTURED: VACCINES - CELL THERAPY - RECOMBINANT PROTEINS & MABS - OTHERS
- TECHNOLOGIES HOUSED & MANUFACTURING SERVICES
- FACILITY SIZE, DESIGN AND CAPACITY PLANNING
SECTION 4: OUR OTHER REPORTS
- BIBILIOGRAPHY
- DISCLAIMER
- ABOUT US
- OUR OTHER REPORTS